Martin Dietrich, MD, PhD, presents key data from the phase 3 MARIPOSA-2 study, which investigated amivantamab plus chemotherapy, with or without lazertinib, versus chemotherapy in patients with EGFR-mutated advanced NSCLC who experienced disease progression on osimertinib.
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.